Category Archives: Central and Eastern Europe
Axon Therapies Announces Positive Early Clinical Data from REBALANCE-HF Randomized Clinical Trial
Below, we are re-publishing with permission the press-release issued by Axon Therapies on May 23, 2022 Late-breaking results presented at the European Society of Cardiology’s Heart Failure Association annual conference and simultaneously published online in the European Journal of Heart … Continue reading
Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ: ABMD) announces the successful results of the first-in-human early feasibility study of the preCARDIA system. The preCARDIA system is designed to improve decongestion in acutely decompensated heart failure (ADHF) patients by intermittently occluding the superior vena cava. … Continue reading
Positive Preliminary Clinical Trial Results Reported for Vascular Dynamics’ Novel Heart Failure Treatment Technology
Endovascular baroreflex modulation data presented Feb 9, 2021 IRVINE, CALIF – (February 9, 2021) – Vascular Dynamics, Inc., a privately held medical device company focused on innovative, endovascular device-based solutions for cardiovascular conditions, has announced positive preliminary results from its … Continue reading
Clinical Accelerator collaborates with Metavention on a study of a novel medical device for hypertension
Clinical Accelerator and Metavention have recently entered into a collaboration allowing Clinical Accelerator to join the program of feasibility studies already under way in the United States, New Zealand and Australia. Our organization will participate in the renal denervation trial … Continue reading
Replicor publishes its REP 301-LTF study achieving durable functional cure of HDV and HBV, inactivation of cccDNA and elimination of integrated HBV DNA
Below, we are re-publishing with permission the press-release issued by Replicor Inc. on November 16, 2020 MONTREAL, November 16th, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, … Continue reading
Clinical Accelerator announces collaboration with Noxopharm to advance idronoxil (NOX66), a novel treatment for COVID-19
Clinical Accelerator is pleased to announce a new collaboration with Noxopharm, a leading Australian drug development company. Noxopharm’s NOX66 therapy has received trial approval and is now in a Phase Ib, open-label trial by Clinical Accelerator in Eastern Europe. The … Continue reading
Axon Therapies Announces Positive Results From First-In-Human Clinical Study in Late-Breaking Clinical Trial Session At 2020 Virtual HFSA Conference
Below, we are re-publishing with permission the press-release issued by Axon Therapies, Inc. on October 09, 2020 Satera™ Ablation System demonstrates success as a frontline treatment of heart failure NEW YORK, Oct. 9, 2020 /PRNewswire/ — Axon Therapies, a Coridea portfolio company focused … Continue reading
Sequana Medical announces strong interim results from RED DESERT alfapump® DSR study and provides business update
Below, we are re-publishing with permission the press-release issued by Sequana Medical on October 22, 2020 RED DESERT: Results from first five patients indicate repeated dose alfapump DSR therapy to be safe and effective Interim data support DSR hypothesis: kidneys … Continue reading
Posted in Central and Eastern Europe, Clinical Accelerator, Medical Devices
Tagged clinical trials
Leave a comment
Clinical Accelerator to collaborate with Second Heart Assist on a Phase I study in Heart Failure
Clinical Accelerator and Second Heart Assist have recently entered into an exciting new collaboration, focused on developing a novel device for heart failure patients. An early feasibility trial will be conducted on Second Heart’s aortic stent based circulatory assist pump. … Continue reading
Clinical Accelerator announces collaboration with LARRK Bio Inc
Clinical Accelerator is excited to announce that it has entered into a collaboration with LARRK Bio Inc, a US based biotech start-up company focusing on skin health and dermatology. The company is currently in “stealth mode”. LARRK Bio is led … Continue reading
clinicalaccelerator.com 
You must be logged in to post a comment.